Description
Bexitrol F HFA 25/250 Inhaler is a sophisticated metered-dose inhaler (MDI) prescribed for the regular maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Each actuation delivers a precise combination of Salmeterol Xinafoate 25 mcg and Fluticasone Propionate 250 mcg. Salmeterol, a long-acting beta-2 agonist (LABA), provides sustained bronchodilation, relaxing airway muscles for easier breathing over 12 hours. Fluticasone, an inhaled corticosteroid (ICS), powerfully reduces inflammation and swelling in the lungs, preventing exacerbations. This synergistic action offers dual benefits: immediate and sustained relief from breathlessness and long-term control of underlying airway inflammation, significantly improving lung function and reducing the frequency and severity of respiratory symptoms. It is a crucial daily controller therapy, not for acute relief.
